Howell A
CRC Department of Medical Oncology, Christie Hospital NHS Trust, M20 4BX, Manchester, UK.
Eur J Cancer. 2000 Sep;36 Suppl 4:S87-8. doi: 10.1016/s0959-8049(00)00241-0.
Anti-oestrogen therapy, tamoxifen in particular, has revolutionised the treatment of breast cancer. However, the partial agonist activity of tamoxifen is associated with an increased risk of endometrial cancer and the acquisition by patients of tamoxifen-resistance. In an attempt overcome these negative aspects of tamoxifen therapy, 'pure' anti-oestrogens have been developed and are currently being investigated for the treatment of breast cancer.
抗雌激素疗法，尤其是他莫昔芬，彻底改变了乳腺癌的治疗方式。然而，他莫昔芬的部分激动剂活性与子宫内膜癌风险增加以及患者产生他莫昔芬耐药性有关。为了克服他莫昔芬治疗的这些负面问题，人们研发了“纯粹”的抗雌激素药物，目前正在对其治疗乳腺癌的效果进行研究。
